Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39


Brain histopathology in three cases of Susac's syndrome: implications for lesion pathogenesis and treatment.

Hardy TA, O'Brien B, Gerbis N, Barnett MH, Reddel SW, Brewer J, Herkes GK, Silberstein P, Garsia RJ, Watson JD, Gupta R, Parratt JD, Buckland ME.

J Neurol Neurosurg Psychiatry. 2015 May;86(5):582-4. doi: 10.1136/jnnp-2014-308240. Epub 2014 Aug 28. No abstract available.


Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.


Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.


Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.


Platelet count kinetics following interruption of antiretroviral treatment.

Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group.

AIDS. 2013 Jan 2;27(1):59-68. doi: 10.1097/QAD.0b013e32835a104d.


Severe Bickerstaff's encephalitis treated with Rituximab: serum and CSF GQ1b antibodies.

Hardy TA, Barnett MH, Mohamed A, Garsia RJ, Davies L.

J Neuroimmunol. 2012 Oct 15;251(1-2):107-9. doi: 10.1016/j.jneuroim.2012.07.008. Epub 2012 Aug 4.


Tumour necrosis factor (TNF) inhibitor therapy in Susac's syndrome.

Hardy TA, Garsia RJ, Halmagyi GM, Lewis SJ, Harrisberg B, Fulham MJ, Barnett MH.

J Neurol Sci. 2011 Mar 15;302(1-2):126-8. doi: 10.1016/j.jns.2010.11.016. Epub 2010 Dec 17.


Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447.


Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.

AIDS. 2009 Jan 2;23(1):71-82. doi: 10.1097/QAD.0b013e32831cc129.


Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group.

AIDS. 2008 Nov 12;22(17):2279-89. doi: 10.1097/QAD.0b013e328311d16f.


Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD.

Ann Intern Med. 2008 Sep 2;149(5):289-99.


Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN.

J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523.


Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.


HIV in the lymphoid compartment.

Garsia RJ.

J HIV Ther. 2005 Jun;10(2):10-5. No abstract available.


Lability of antiretroviral drug resistance mutations--correlates with immunological and virological responses.

Al Mazari A, Zomaya AY, Charleston M, Salem H, Maher A, Garsia RJ.

Curr HIV Res. 2007 Jul;5(4):430-9.


The uptake of HIV post-exposure prophylaxis within a sexual assault setting in Sydney, Australia.

Templeton DJ, Davies SC, Garvin AL, Garsia RJ.

Int J STD AIDS. 2005 Feb;16(2):108-11. Erratum in: Int J STD AIDS. 2005 May;16(5):344.


Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia.

Robotin MC, Law MG, Milliken S, Goldstein D, Garsia RJ, Dolan GM, Kaldor JM, Grulich AE.

HIV Med. 2004 Sep;5(5):377-84.


B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS.

Grulich AE, Wan X, Law MG, Milliken ST, Lewis CR, Garsia RJ, Gold J, Finlayson RJ, Cooper DA, Kaldor JM.

AIDS. 2000 Jan 28;14(2):133-40.


Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort.

Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS.

N Engl J Med. 1999 Jun 3;340(22):1715-22.


Eosinophilic leukaemoid reaction and interleukin-5 in metastatic melanoma.

Oakley SP, Garsia RJ, Coates AS.

Med J Aust. 1998 Nov 2;169(9):501. No abstract available.


Supplemental Content

Loading ...
Support Center